Managing cardiovascular and renal risk: the potential of direct renin inhibition (Q37510348)

20 August 2017

1 reference

title

Managing cardiovascular and renal risk: the potential of direct renin inhibition (English)

1 reference

20 August 2017

1 reference

Peter S Sever

1

1 reference

20 August 2017

Alan H Gradman

series ordinal

2

1 reference

20 August 2017

Michel Azizi

series ordinal

3

1 reference

20 August 2017

publication date

1 June 2009

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

65-76

1 reference

Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

New drugs for hypertension: what do they offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Physiology and pathophysiology of the adipose tissue renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin, prorenin and the putative (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

The renin rise with aliskiren: it's simply stoichiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Relationship between morning hypertension identified by home blood pressure monitoring and brain natriuretic peptide and estimated glomerular filtration rate: the Japan Morning Surge 1 (JMS-1) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Conformational changes in prorenin during renin inhibition in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Aliskiren for renin inhibition: a new class of antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Aliskiren: the first renin inhibitor for clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Coronary heart disease events preventable by control of blood pressure and lipids in US adults with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Clinical pharmacokinetics and pharmacodynamics of aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Dual inhibition of the renin system by aliskiren and valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Drug-induced hyperkalemia: old culprits and new offenders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Surrogate markers for cardiovascular disease: structural markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320309104662

21 January 2018

Identifiers

DOI

10.1177/1470320309104662

1 reference

release_35nnzk3mbrhgvj5eehwv2e7st4

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/35nnzk3mbrhgvj5eehwv2e7st4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference